)
In February 2015, American biotechnology company Gilead Lifesciences appointed Mylan as its exclusive distributor of Sovaldi in India.
The drug is indicated for the treatment of chronic hepatitis C infection, a blood-born infectious disease, as a component of a combination antiviral treatment regimen, according to Mylan.
"Mylan has long-standing history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality, affordable HIV/AIDS antiretrovirals and now extending our partnership to include hepatitis C treatments," Rajiv Malik, Mylan president, said in a statement on Monday.
Additional hepatitis C arrangements with Gilead include a licensing and technology transfer agreement that grants Mylan the non-exclusive rights to manufacture and distribute generic sofosbuvir and generic ledipasvir/sofosbuvir and, upon FDA approval, the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816 in 91 developing countries, according to the statement.
